RhoVac AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.05.21	RhoVac Confirms Forecast - BRaVac Phase IIb study recruitment to close in Quarter 3 2021 (PR Newswire)
31.05.21	RhoVac Confirms Forecast - BRaVac Phase IIb study recruitment to close in Quarter 3 2021 (PR Newswire)
11.05.21	RhoVac's events during May - August (PR Newswire)
03.05.21	RhoVac brought to the attention of the European Innovation Council during World Immunization Week (PR Newswire)
21.04.21	Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer (PR Newswire)
21.04.21	Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer (PR Newswire)
21.04.21	Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer (PR Newswire)
08.03.21	Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study (PR Newswire)
08.03.21	Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study (PR Newswire)
08.03.21	Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study (PR Newswire)
07.01.21	First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom (PR Newswire)
07.01.21	First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom (PR Newswire)
07.01.21	First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom (PR Newswire)
25.11.20	RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA (PR Newswire)
25.11.20	RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA (PR Newswire)
25.11.20	RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA (PR Newswire)
13.11.20	Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer (PR Newswire)
13.11.20	Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer (PR Newswire)
13.11.20	Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer (PR Newswire)
26.10.20	RhoVac Participates in BIO Europe Digital (PR Newswire)
26.10.20	RhoVac Participates in BIO Europe Digital (PR Newswire)
26.10.20	RhoVac Participates in BIO Europe Digital (PR Newswire)
26.10.20	Article on RhoVac's Phase I/II study to be published in November (PR Newswire)
26.10.20	Article on RhoVac's Phase I/II study to be published in November (PR Newswire)
26.10.20	Article on RhoVac's Phase I/II study to be published in November (PR Newswire)
12.10.20	The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study (PR Newswire)
12.10.20	The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study (PR Newswire)
12.10.20	The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study (PR Newswire)
17.09.20	First patient in treatment in RhoVac's clinical phase IIb study in Sweden (PR Newswire)
17.09.20	First patient in treatment in RhoVac's clinical phase IIb study in Sweden (PR Newswire)
17.09.20	First patient in treatment in RhoVac's clinical phase IIb study in Sweden (PR Newswire)
04.09.20	RhoVac appoints Professor Georg Hollaender to its Scientific Advisory Board (PR Newswire)
04.09.20	RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board (PR Newswire)
04.09.20	RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board (PR Newswire)
10.08.20	First patient in treatment in RhoVac's clinical phase IIb study in the USA (PR Newswire)
10.08.20	First patient in treatment in RhoVac's clinical phase IIb study in the USA (PR Newswire)
10.08.20	First patient in treatment in RhoVac's clinical phase IIb study in the USA (PR Newswire)
01.07.20	A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd (PR Newswire)
01.07.20	A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd (PR Newswire)
01.07.20	A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd (PR Newswire)
01.07.20	RhoVac Marketed in International Press (PR Newswire)
01.07.20	RhoVac Marketed in International Press (PR Newswire)
01.07.20	RhoVac Marketed in International Press (PR Newswire)
23.04.20	First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany (PR Newswire)
23.04.20	First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany (PR Newswire)
23.04.20	First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany (PR Newswire)
02.04.20	Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected to be Managed With Existing Funding (PR Newswire)
02.04.20	Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected to be Managed With Existing Funding (PR Newswire)
02.04.20	Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected to be Managed With Existing Funding (PR Newswire)
06.02.20	RhoVac Announces Appointment of Professor Anne J. Ridley to its Scientific Advisory Board (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.15	2.19 %	K V
Logitech Intl	72.20	1.66 %	K V
Lonza Grp	526.60	1.00 %	K V
Swiss Re	129.35	0.82 %	K V
UBS Group	28.35	0.18 %	K V
Givaudan	3’901.00	-0.81 %	K V
Swiss Life Hldg	725.40	-1.12 %	K V
Holcim	89.78	-1.12 %	K V
Novartis	91.93	-1.87 %	K V
Sonova Hldg	306.20	-1.89 %	K V

Nachrichten zu RhoVac AB

Aktien Top/Flop

Meistgelesene Nachrichten